Charles Schwab
STLN

Charles Schwab’s Starling Oncology STLN Stock Holding History

Charles Schwab’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
226,007
+11,092
+5% +$46.6K ﹤0.01% 2944
2026
Q1 		$660K Buy
214,915
+6,650
+3% +$20.4K ﹤0.01% 3020
2025
Q4 		$741K Buy
208,265
+20,731
+11% +$76.9K ﹤0.01% 3022
2025
Q3 		$654K Buy
187,534
+40,000
+27% +$137K ﹤0.01% 3083
2025
Q2 		$302K Buy
+147,534
New +$369K ﹤0.01% 3306
2023
Q2 		– Sell
-87,594
Closed -$59.4K – 3680
2023
Q1 		$59.4K Hold
87,594
– – ﹤0.01% 3323
2022
Q4 		$145K Hold
87,594
– – ﹤0.01% 3229
2022
Q3 		$406K Buy
87,594
+46,333
+112% +$272K ﹤0.01% 3061
2022
Q2 		$209K Buy
+41,261
New +$300K ﹤0.01% 3237

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Charles Schwab's STLN Position: Q2 2026 in Review

Charles Schwab increased its Starling Oncology (STLN) stake by 5.2% in Q2 2026, buying an estimated $46.6K and bringing the position to 226,007 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

Charles Schwab first reported a position in STLN in Q2 2022 and has held it in 9 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Charles Schwab held 226,007 shares of Starling Oncology worth $1.23M as of Q2 2026.
  • Charles Schwab bought 11,092 Starling Oncology shares in Q2 2026, an estimated $46.6K.
  • Starling Oncology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2944 holding.
  • Charles Schwab first reported a position in Starling Oncology in Q2 2022 and has held it in 9 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.